2026-10-21 → 10-22 Capital
Abbott to Spin Off Nutrition Business, Cuts 2026 Sales Growth Outlook Q3 call confirms spin-off plan; cuts sales growth outlook amid diabetes pricing and EP challenges
D1 -1.9% · +5d +2.1%
› 2 waves of this story2026-10-21 Nutrition unit with ~$8.5B annual sales to be separated, sharpening focus on high-growth areas2026-10-22 Q3 call confirms spin-off plan; cuts sales growth outlook amid diabetes pricing and EP challenges2026-10-22 8-K filing
8-K: Item 8.01, Item 9.01 D1 +2.0% · since +0.1%
2026-10-13 → 10-21 Earnings Bear
Abbott Q3: Adj EPS $1.42, Lowers 2026 Sales Growth Forecast Comparable sales +7%, but medical device weakness prompts guidance cut
D1 +0.8% · +5d -0.2%
› 7 waves of this story2026-10-13 Preview cites growth drivers, but no actual results yet2026-10-17 Multiple sources confirm ABT's earnings date, market awaits results2026-10-17 Multiple sources confirm earnings date approaching; market watches guidance2026-10-19 Multiple independent sources confirm ABT reports Q3 earnings Wednesday (10/21), raising market attention2026-10-19 Analysts revise expectations ahead of the report, raising market attention2026-10-21 Multiple sources confirm pre-market release; this is the scheduled earnings date after prior anticipation2026-10-21 Comparable sales +7%, but medical device weakness prompts guidance cut2026-10-21 Earnings
Earnings report 第三季度销售额增长7%，调整后每股收益为1.42美元，符合预期。
D1 -1.9% · +5d +2.1%
2026-10-21 8-K filing
8-K: Item 2.02, Item 9.01 D1 -1.9% · +5d +2.1%
2026-10-07 Product
ABT Launches Ensure Max Protein 3-in-1 Muscle Support New powder combines 30g protein, 5g creatine, 3g HMB, expanding nutrition portfolio
D1 +0.6% · +5d +4.3%
2026-10-02 Analyst
Rothschild & Co upgrades to Buy D1 +0.8% · +5d +2.2%
2026-10-02 Analyst Bull
ABT Receives Multiple Analyst Upgrades and Price Target Hikes Rothschild upgrades to Buy with $127 PT; multiple firms raise ratings same day
D1 +0.8% · +5d +2.2%
2026-09-14 → 09-15 Regulation
Abbott's $385M Baby Formula Settlement, Market Fears Overblown Social media notes $385M settlement is immaterial for $180B market cap firm, rebutting earlier liability fears
D1 +1.1% · +5d -0.1%
› 2 waves of this story2026-09-14 Settlement without fault finding; criminal probe closed, removing legal overhang2026-09-15 Social media notes $385M settlement is immaterial for $180B market cap firm, rebutting earlier liability fears2026-09-09 Product Bull
Abbott's TactiFlex Duo Receives FDA Approval, Expanding AFib Ablation Portfolio FDA nod for TactiFlex Duo with dual energy options may boost U.S. adoption
D1 -0.3% · +5d -2.7%
2026-08-31 Product Bull
Abbott launches whole-milk infant formula, closer to breast milk fats First ready-to-feed liquid formula with whole milk in U.S., priced similar to Similac powder, boosting product portfolio
D1 -1.9% · +5d -4.4%
2026-08-30 Capital
Two Asset Managers Initiate Abbott Positions in Q2 Frazier forms new stake; CM Wealth invests $1.08M, reflecting quarterly institutional moves
D1 -1.9% · +5d -4.4%
2026-08-17 → 08-28 Company
Abbott declines 2.2% but up 5.65% over past month; long-term momentum highlighted Stock fell 2.2% vs S&P 500 gain; long-term momentum strength remains emphasized
D1 -0.8% · +5d +5.7%
› 3 waves of this story2026-08-17 Multi-year effort integrates nutrition into primary care at community health centers2026-08-26 AF treatment device market growth forecast benefits Abbott as key player2026-08-28 Stock fell 2.2% vs S&P 500 gain; long-term momentum strength remains emphasized2026-08-27 Product Bull
Abbott's Amulet 360 Receives CE Mark for AFib Stroke Prevention Next-gen LAA closure device gains EU approval, expanding market access
D1 -2.2% · +5d -2.5%
2026-08-26 Product Bull
FDA Authorizes Abbott's First Dual Ketone-Glucose Continuous Monitor Libre Duo receives FDA clearance as world's first biowearable monitoring both glucose and ketones to prevent DKA
D1 -1.7% · +5d -3.2%
2026-08-26 Capital Bull
Bank Hapoalim Boosts Abbott Stake by 80.7% Institutional quarterly holding change shows increased allocation to Abbott
D1 -1.7% · +5d -3.2%
2026-08-25 Insider selling
Insider selling $46.2M (1) D1 -0.5% · +5d -6.2%
2026-08-21 8-K filing
8-K: Item 7.01, Item 8.01, Item 9.01 D1 +2.2% · +5d -3.6%
2026-07-23 → 08-17 Capital
Institutional Q2 Filings Show Mixed Moves in Abbott Crossmark raised stake 2.8%; PA pension, Fifth Third trimmed positions
D1 +0.2% · +5d +4.8%
› 5 waves of this story2026-07-23 B&D White Capital opens new position, ABN Amro raises stake by 10.9%, showing institutional interest2026-07-23 B&D White Capital opens new position; ABN Amro raises stake by 10.9%, extending institutional buying trend2026-07-31 BofA's 13F shows 2.8% cut, echoing recent institutional activity2026-08-03 Chelsea Counsel sold 5,000 shares, cutting holdings by 23.5% to 16,311 shares per 13F2026-08-17 Crossmark raised stake 2.8%; PA pension, Fifth Third trimmed positions2026-08-13 Analyst
Wolfe Research upgrades to Outperform D1 +0.3% · +5d +2.6%
2026-08-11 Company
Abbott and Google Partner on Glucose Insights AI Multi-source confirms partnership launch with large-scale study for AI health guidance
D1 +1.0% · +5d +2.7%
› 2 waves of this story2026-08-11 Multi-year collab merges Lingo biowearable with Google Health tech; large-scale study planned2026-08-11 Multi-source confirms partnership launch with large-scale study for AI health guidance2026-08-03 Analyst Bull
Abbott Down 16% YTD, Analyst Sees 35% Upside Street consensus PT $118.42 implies ~12% upside from $105.70
D1 +1.3% · +5d +1.4%
2026-07-18 → 07-28 Earnings Bull
Abbott Reports Record Q2, Raises Guidance; Innovation Across Diabetes, Oncology, Heart Care Multiple sources confirm record results and raised guidance, highlighting innovation in diabetes, oncology diagnostics, and heart devices
D1 +1.0% · +5d +2.8%
› 4 waves of this story2026-07-18 Strong medical device sales and margin expansion drove shares gap up; adjusted gross margin hit 58%2026-07-24 Zacks reports ABT raised outlook, consistent with prior Q2 beat event2026-07-27 Zacks notes stronger earnings setup post-beat, but questions if valuation upside justifies buying.2026-07-28 Multiple sources confirm record results and raised guidance, highlighting innovation in diabetes, oncology diagnostics, and heart devices2026-07-28 Regulation Bull
Implicity's Next-Gen ILR ECG Analyzer Receives FDA Clearance AI software reduces false alerts from implantable cardiac monitors by up to 76%, potentially impacting Abbott's device ecosystem
D1 +2.7% · +5d -1.7%
2026-07-10 → 07-21 Earnings Bear
Abbott Laboratories Shares Sold by Multiple Institutions in Q1 AlTi Global cut stake by 54.7%, Andra AP fonden by 36.4%, institutional holdings updates continue
D1 -0.5% · +5d +7.2%
› 10 waves of this story2026-07-10 Multiple independent sources confirm Abbott Labs reports earnings the week of July 132026-07-12 Earnings week approaching, Rep. Khanna bought ABT, raising market attention2026-07-13 Multiple independent sources confirm ABT reports this week, plus congressional disclosure of ABT sale, adding new facts to the event line2026-07-16 Q2 comparable sales +4.8%, adj EPS $1.31, raises FY profit forecast, earnings event concluded2026-07-17 Verified Q2 net sales $12.59B, adj EPS $1.31; FY guide raised to $5.45-$5.60; Diagnostics rev +42.3% YoY2026-07-18 Post-earnings beat and guidance raise triggered analyst forecast hikes and a sharp gap-up open2026-07-19 AIA, Allspring, Assetmark raised Q1 stakes; Ascent trimmed; mixed but net-positive institutional activity2026-07-19 New 13F filings show AIA, Allspring, Assetmark increased stakes while Ascent reduced, extending the institutional positioning theme2026-07-21 AlTi Global cut 54.7%, Andra AP fonden cut 36.4%, contrasting earlier accumulation reports2026-07-21 AlTi Global cut stake by 54.7%, Andra AP fonden by 36.4%, institutional holdings updates continue2026-07-13 → 07-17 Earnings
Abbott Set to Report Q2 Earnings This Week; Key Metrics in Focus Revenue and adj. EPS beat estimates, diagnostics surged, FY adj. EPS guidance raised.
D1 -1.9% · +5d +10.4%
› 3 waves of this story2026-07-13 Multiple independent sources confirm Abbott's earnings week, with analysts focusing on key business metrics beyond top and bottom lines.2026-07-16 Q2 comparable sales +4.8%, adj EPS $1.31, raises full-year guidance2026-07-17 Revenue and adj. EPS beat estimates, diagnostics surged, FY adj. EPS guidance raised.2026-07-16 Earnings
Earnings report Q2 comparable sales growth of 4.8%, accelerating from low single digits in prior quarters, with adjusted EPS of $1.31 exceeding guidance midpoint
D1 +10.7% · +5d +1.9%
2026-07-16 8-K filing
8-K: Item 2.02, Item 9.01 D1 +10.7% · +5d +1.9%
